Comparative effects of verapamil, diltiazem, and nifedipine on hemodynamics and left ventricular function during acute myocardial ischemia in dogs
- PMID: 6690104
- DOI: 10.1161/01.cir.69.2.382
Comparative effects of verapamil, diltiazem, and nifedipine on hemodynamics and left ventricular function during acute myocardial ischemia in dogs
Abstract
The calcium channel-blocking drugs verapamil, diltiazem, and nifedipine are being used with increasing frequency in patients with angina pectoris due to coronary artery disease. Although each of these agents possesses negative inotropic potential, their relative effects on myocardial function in relation to their vasodilator potencies are unknown. We understood to study this in 20 conscious dogs that had partial occlusions of their circumflex coronary arteries during therapy with placebo, verapamil, nifedipine, or diltiazem. Myocardial blood flow was measured by use of microspheres, and left ventricular function was measured by radionuclide angiography. Drug effects were compared at doses causing equal decreases in mean arterial pressure and coronary vascular resistance of nonischemic myocardium. Global ejection fraction and ejection fraction of the ischemic region were significantly decreased by verapamil (p less than .01) and increased by nifedipine (p less than .001); diltiazem caused no significant changes. Verapamil significantly increased peak diastolic filling rate (p less than .001); nifedipine also increased diastolic filling rate, but only at doses that markedly decreased mean arterial pressure and coronary vascular resistance. The effect of diltiazem on diastolic filling rate was not significantly different than placebo. For doses causing an equal decrease in mean arterial pressure, verapamil decreased heart rate (p less than .001), and diltiazem and nifedipine increased heart rate (p less than .001). We conclude that the relative potencies of these three calcium channel blocking agents on left ventricular systolic and diastolic function during myocardial ischemia are different when compared with their relative vasodilator potencies. These differences may have important clinical implications.
Similar articles
-
Comparative effects of calcium-channel blocking agents on left ventricular function during acute ischemia in dogs with and without congestive heart failure.Am J Cardiol. 1985 Jan 25;55(3):10B-16B. doi: 10.1016/0002-9149(85)90608-3. Am J Cardiol. 1985. PMID: 3969856
-
Chronotropic, inotropic, and vasodilator actions of diltiazem, nifedipine, and verapamil. A comparative study of physiological responses and membrane receptor activity.Circ Res. 1983 Feb;52(2 Pt 2):I29-39. Circ Res. 1983. PMID: 6831652
-
Differential cardiovascular effects of calcium channel blocking agents: potential mechanisms.Am J Cardiol. 1982 Feb 18;49(3):499-506. doi: 10.1016/s0002-9149(82)80002-7. Am J Cardiol. 1982. PMID: 6277175
-
The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease. A review.Drugs. 1986 Jul;32(1):66-101. doi: 10.2165/00003495-198632010-00004. Drugs. 1986. PMID: 2874975 Review.
-
Calcium-channel blocking agents.Clin Pharm. 1982 Jan-Feb;1(1):17-33. Clin Pharm. 1982. PMID: 6764159 Review.
Cited by
-
Salvianolic acid A targeting the transgelin-actin complex to enhance vasoconstriction.EBioMedicine. 2018 Nov;37:246-258. doi: 10.1016/j.ebiom.2018.10.041. Epub 2018 Oct 23. EBioMedicine. 2018. PMID: 30361065 Free PMC article.
-
Are calcium antagonists cardioprotective?J R Coll Physicians Lond. 1985 Apr;19(2):85-9. J R Coll Physicians Lond. 1985. PMID: 3889321 Free PMC article. Review. No abstract available.
-
Neuropeptide-Y. A peptide found in human coronary arteries constricts primarily small coronary arteries to produce myocardial ischemia in dogs.J Clin Invest. 1989 Apr;83(4):1217-24. doi: 10.1172/JCI114004. J Clin Invest. 1989. PMID: 2703530 Free PMC article.
-
An Updated Review on the Role of Non-dihydropyridine Calcium Channel Blockers and Beta-blockers in Atrial Fibrillation and Acute Decompensated Heart Failure: Evidence and Gaps.Cardiovasc Drugs Ther. 2023 Dec;37(6):1205-1223. doi: 10.1007/s10557-022-07334-y. Epub 2022 Mar 31. Cardiovasc Drugs Ther. 2023. PMID: 35357604 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources